PPARA and hypertriglyceridemia: Treatment with fenofibrate (or other PPAR-α agonist equivalents) in persons with hypertriglyceridemia has shown a therapeutic efficacy to promote favorable changes in the serum TG (41–53% decrease), LDL-C (6–20% decrease), and HDL-C (5–20% increase) concentrations in clinical trials of varied durations, clinical endpoints, and patient populations with adverse lipid concentrations16–23.